在患有胰腺癌的患者中,白内障指数和骨质疏松症之间的预后关系
Teruhisa Sakamoto1, Mikiya Kishino2, Yuki Murakami2
1Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan tesakamo@tottori-u.ac.jp.
Anticancer research
|March 4, 2025
概括
缓解症指数 (CXI) 和骨质疏松症 (低骨矿物密度) 是胰腺癌患者的显著预后因素. 结合CXI和骨质疏松症评估可以改善生存预测,低CXI和骨质疏松症表明结果不佳.
科学领域:
- 在瘤学瘤学.
- 代谢综合征是代谢综合征的一种.
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 癌症缓冲症是一种复杂的综合征,影响患者的治疗结果.
- 低骨矿物质密度 (BMD) 的骨质疏松症越来越多地被认为与癌症缓解症和生存有关.
- 缓冲症指数 (CXI) 是癌症缓冲症的一个新型生物标志物.
研究的目的:
- 在胰腺癌患者中,研究 cachexia 指数 (CXI) 和骨矿物密度 (BMD) 之间的预后关系.
- 评估CXI和BMD的综合预后值,以预测生存结果.
主要方法:
- 对121名因胰腺癌而接受胰腺切除术的患者进行了回顾性分析.
- 评估缓解症指数 (CXI) 和骨矿物密度 (BMD) 的预后意义.
主要成果:
- 高CXI与明显更好的5年整体存活率有关.
- 骨质疏松症 (低BMD) 与更糟糕的5年整体存活率显著相关.
- 低CXI和骨质疏松症的组合表明预后最差,并且这种联合评估与单个标志物相比改善了生存预测的准确性.
结论:
- 缓解症指数 (CXI) 和骨质疏松症是胰腺癌中密切相关的预后因素.
- 低CXI和骨质疏松症患者的生存率显著降低.
- 对CXI和BMD的联合评估为胰腺癌患者提供了增强的预后价值.
相关概念视频
01:21Cancer Survival Analysis
319
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
319
01:29Chronic Pancreatitis II: Collaborative Care
56
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
56